Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCH 486757 in persistent postviral cough
NCT00230230Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2005
- Primary completion
- Apr 2007
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of SCH-486757 in Postinfectious cough (3 arms), sponsored by Merck & Co. Primary endpoint: Reduction of cough severity score at 5 days. Started Oct 2005; status: completed.
02
Drugs
SCH-486757
03
Conditions
Postinfectious cough
Beyond the preview
Go deeper on NCT00230230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00230230.